Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00685750 · ClinicalTrials.gov registry record · NA

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

A NA study, sponsored by GlaxoSmithKline.

Terminated
Registry status
NA
Development phase
88
Enrollment target

NCT00685750 is a NA study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 88 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00685750, a NA study, was terminated before completion, sponsored by GlaxoSmithKline.

TERMINATED
Registry status
NA
Development phase
88 participants
Enrollment target

Study Summary

This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma. The data obtained in this study will be used to guide future development of immunotherapies for melanoma or NSCLC patients. Moreover, the analyses will contribute to definition of markers potentially predictive of clinical response to specific anticancer therapies.

Interventions

  • PROCEDURE Collection of tumor and blood samples

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2008-04-28
Est. Completion 2013-12-17
Phase NA

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT00685750

The ClinicalTrials.gov registry entry for NCT00685750 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Collection of tumor and blood samples is the first listed.

NCT00685750 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00685750 about?

NCT00685750 is a clinical study titled "Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma". This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma. The data obtained in this study will be used to guide future development of immunotherapies for melanoma or NSCLC ...

What is the current status of trial NCT00685750?

This trial is currently terminated. It is a NA study. The enrollment target is 88 participants. The study started on 2008-04-28. Estimated completion is 2013-12-17.

What interventions are being tested in trial NCT00685750?

The interventions under investigation include: Collection of tumor and blood samples (PROCEDURE).

Who is sponsoring clinical trial NCT00685750?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.